The Food and Drug Administration is investigating serious adverse events involving Limbrel, a capsule being marketed as a medical food to manage the metabolic processes associated with osteoarthritis. Health care providers who know their patients are taking the product should advise them to stop taking it immediately, FDA said. While a range of adverse events have been reported, two serious and potentially life-threatening medical conditions are among them: drug-induced liver injury and hypersensitivity pneumonitis. For more information, see the FDA safety alert.

Related News Articles

Headline
More than 100 members of Congress signed a letter submitted Dec. 12 to the Department of Education on concerns about the department’s proposal to omit post-…
Headline
A blog published Oct. 21 breaks down the pressures driving physicians toward employment, including financial strain and administrative burden. The blog, co-…
Headline
The American Organization for Nursing Leadership and Laudio Oct. 7 released a report that shows eight predictive burnout metrics and shares strategies from…
Headline
The House Energy and Commerce Subcommittee on Health Sept. 10 advanced the Title VIII Nursing Workforce Reauthorization Act (H.R. 3593), AHA-supported…
Headline
The Centers for Medicare & Medicaid Services July 14 released its calendar year 2026 proposed rule for the physician fee schedule. As required by…
Headline
A Q&A in the latest edition of AHA Trustee Insights highlights how boards value the perspective of nurses. Experts interviewed include Kimberly Cleveland,…